Asia Pacific Cannabidiol (CBD) Market Overview

The Asia Pacific cannabidiol market was valued at USD 440.5 million in 2023 and is projected to grow significantly, reaching USD 1.98 billion by 2030. This represents a robust compound annual growth rate (CAGR) of 24.1% from 2025 to 2030. The market’s expansion is driven by a shift in regional attitudes toward hemp-based products, with rising acceptance and progressive legalization trends gaining traction across various Asia Pacific nations. Increasing consumer awareness regarding the potential therapeutic and wellness benefits of cannabidiol has led to heightened demand, fueling innovation and product diversification within the sector.

In response to this surging demand, companies operating in the Asia Pacific CBD space are focusing on developing a wide array of cannabidiol-infused offerings. These include edibles, topical formulations, and infused beverages, which cater to both medicinal and lifestyle-oriented consumers. The rise of digital commerce has further catalyzed market growth, enabling brands to reach broader customer segments via online platforms, boosting product accessibility and sales.

Asia Pacific ranks as the third largest regional market globally for cannabidiol. CBD, a non-intoxicating compound derived from the hemp plant, is being marketed in various forms such as capsules, oils, edibles, and vaping liquids. Prominent players like Eos Scientific, operating under the Ambiance Cosmetics brand, have launched six distinct CBD-infused cosmetic product lines, including moisturizers, balms, and oils. As public interest and awareness of CBD’s therapeutic properties continue to rise, investment in research and development (R&D) has also seen an uptick. This growing focus on scientific validation and product innovation has intensified market competition, with numerous companies entering the space and offering similar solutions, which has further contributed to market expansion.

However, despite this upward momentum, the regulatory environment in several Asian and African nations remains a significant barrier. Many countries in these regions continue to enforce strict prohibitions on cannabis-based products, including CBD. These restrictive legal frameworks are often accompanied by harsh penalties for possession or consumption of CBD, even when intended for medical use. For example, Indonesia's drug laws are among the most stringent, with penalties including life imprisonment, fines up to USD 1.2 million, and even the death penalty for violations involving illegal drugs such as cannabis. Such policies severely limit the growth potential of the medical cannabis sector in these markets.

In countries like India, regulatory ambiguity persists, with no clear framework in place for the legal use of CBD. As a result, patients are often forced to import CBD-based medications, usually after obtaining special approvals. This process can be both time-consuming and costly, making these products less affordable and accessible to the general population.

Key Market Trends and Insights

• Australia is projected to be the fastest-growing CBD market within the Asia Pacific region, with an impressive CAGR of 34.1% from 2024 to 2030. Since the legalization of medical cannabis in 2016, the number of patients seeking prescriptions for CBD-based treatments has increased significantly, reflecting growing public and professional acceptance.
• In 2023, hemp-derived CBD products led the market, accounting for a dominant 2% share of the CBD oil segment’s total revenue. This trend is expected to continue, driven by rising demand from the pharmaceutical sector and growing consumer interest in the health benefits of hemp-derived cannabidiol.
• The pharmaceutical end-use segment, within the B2B space, emerged as the market leader in 2023, contributing 7% of the total revenue. The increasing volume of clinical trials exploring CBD’s efficacy in managing various health conditions is expected to bolster demand in this segment over the forecast period.
• Overall, the B2B segment held the highest revenue share of 7% in 2023 and is anticipated to record the fastest growth during the forecast years. This growth is attributed to a rise in the number of wholesalers offering CBD oil, along with the increased demand for CBD as a raw material in the production of pharmaceuticals, cosmetics, and wellness products.

Market Size & Forecast

• 2024 Market Size: USD 35 Billion
• 2030 Projected Market Size: USD 14 Billion
• CAGR (2025-2030): 98%
• China: Largest market in 2023
• Australia: Fastest growing market

Order a free sample PDF of the Asia Pacific Cannabidiol Market Intelligence Study, published by Grand View Research.

Key Cannabidiol Company Insights

Key cannabidiol (CBD) companies are focusing on numerous initiatives such as distribution partnerships and product innovation to maintain their position in the market. For instance, in October 2022, Charlotte's Web Holdings, Inc. announced a distribution partnership with Gopuff Retail Company. This strategy enables companies to increase their capabilities, expand product portfolios, and improve competencies. Key players in the CBD medicine market offer customers diverse, technologically advanced, innovative products. Companies prominently adopt this strategy to expand their customer base. 

Key Players

• Aurora Cannabis
• Tilray
• CV Sciences, Inc.
• CHARLOTTE’S WEB.
• Canopy Growth Corporation
• Maricann, Inc.
• Organigram Holding, Inc.
• Isodiol International, Inc.
• Elixinol
• NuLeaf Naturals, LLC
• Cannoid, LLC
• Endoca

Browse Horizon Databook on Global Asia Pacific Cannabidiol Market Size & Outlook

Conclusion

The Asia Pacific cannabidiol market is on a strong growth trajectory, propelled by shifting consumer preferences, expanding product portfolios, and increasing adoption of online sales channels. While progressive markets like Australia are leading the way in legalization and usage, stricter regulatory landscapes in other parts of Asia pose challenges. Nevertheless, with ongoing R&D, growing pharmaceutical applications, and rising awareness about CBD’s potential benefits, the market is expected to witness sustained growth through 2030.